This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

The FDA has started a review of Bristol-Myers Squibb's immunotherapy duo Opdivo and Yervoy as a therapy for newly diagnosed unresectable liver cancer ... plus VEGF inhibitor bevacizumab, which ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), the most ...

Patients with low C-reactive protein or a high cancer-associated fibroblast signature score had relatively greater ... The phase Ib COSMIC-021 study evaluated cabozantinib plus atezolizumab in ...

Sorafenib is US FDA approved for the treatment of advanced renal cell carcinoma and unresectable hepatocellular ... plus placebo in MBC patients who have progressed during or after bevacizumab ...

1Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Patients received oral cabozantinib 40 mg once daily and intravenous atezolizumab 1,200 mg once every 3 weeks. The primary end point was objective response rate (ORR), as assessed by the investigator ...

Radiation plus combination immunotherapy may help preserve bladder in some patients with muscle-invasive bladder cancer. ScienceDaily . Retrieved February 18, 2025 from www.sciencedaily.com ...